cyrilzakka/clinical-trials huggingface dataset:
TMS Treatment in Multiple System Atrophy With Fatigue

Transcranial magnetic stimulation (TMS) is a procedure that has been shown to improve fatigue in chronic sufferers. It uses a plastic covered coil that sends a magnetic pulse through the skull into the brain and by targeting particular areas in the brain it can be used to help modulate the perception of fatigue.

The study intends to use this technique to treat such a disabling symptom in patients who suffer from Multiple System Atrophy (MSA). Initially the aim is to study this technique in 22 MSA patients who are suffering from fatigue . These patients would require an resting-state funtional MRI before and after the stimulation. The stimulation would be performed ten sessions and the patients would be assessed by a clinician using well recognized clinical tools.

It is anticipated that there will be a meaningful improvement in fatigue. It is also anticipated that TMS is a safety technique to use in MSA patients . Our findings will revealed that fatigue may be associated with an altered default mode network and sensorimotor network connectivity in MSA patients. We hypothesize that these divergent motor and cognitive networks connectivity changes and their adaptive or maladaptive functional outcome may play a prominent role in the pathophysiology of fatigue in MSA.


Eligibility Criteria:
Inclusion Criteria:

1. Patients with Multiple system atrophy diagnosed as "possible" or "probable" according to the 2008 MDS clinical diagnostic criteria;
2. Age ≥30Aged ≤ 75years old;
3. right handedness
4. MMSE\>24
5. the dosage and species of anti-parkinson drug is maintained during the treatment;
6. The patient or his/her legal guardian agreed to participate in the trial and signed the informed consent.Ability to follow research plans and visit plans.
7. FSS≥4

Exclusion Criteria:

1. Serious medical and mental illness;
2. History of stroke, intracranial tumor and other central nervous system;
3. Patients with suicidal tendencies and psychotic symptoms.
4. MRI for contraindications, such as metal implants, claustrophobia, etc
5. Contraindications for TMS (such as history of seizures, pregnant women, installation of pacemakers, metal inclusions in the body, intracranial hypertension, severe bleeding tendency, etc.)
6. Patients who received TMS treatment for nearly half a year.
Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072)

The purpose of this study is to test the effectiveness of a marketed drug in the treatment of a menstrual migraine attack.


Eligibility Criteria:
Inclusion Criteria:

* Female patient at least 18 years old
* Patient has menses approximately monthly
* Patient has at least a 6 month history of migraine and at least a 6 month history of menstrual migraine

Exclusion Criteria:

* Pregnant and/or nursing mother
* Cardiovascular disease
* Uncontrolled hypertension
Optima Coronary Artery Disease (CAD) (Optimal Mechanical Evaluation)

To evaluate the impact of left ventricular (LV) lead location on LV mechanical function.


Eligibility Criteria:
Inclusion Criteria

1. Ischemic Cardiomyopathy
2. Left ventricular ejection fraction less than 40%
3. Clinical indication for invasive electrophysiology testing
4. Patient is at least 18 years of age

Exclusion Criteria

1. Unstable angina, acute myocardial infarction and/or revascularization procedure within 3 months
2. CVA or TIA within the past 6 months
3. Prosthetic heart valve
4. Patient is status post heart transplant
5. Women who are pregnant or with child -bearing potential and who are not on a reliable form of birth control. Women of child-bearing potential are routinely tested for pregnancy as part of the standard of care prior to EPS procedures being performed.
Prevalence and Severity of Cramps in Chronic Kidney Disease Patients

Cramps are a frequent and severe complication in CKD patients. Their characteristics : triggering factors, associated factors, are not well known. There is no recognized effective treatment. Using a questionnaire, the investigators wish to determine prevalence, severity and associated factors of cramps in our CKD patients. Better knowledge about cramps in CKD patients will allow to better support, and give a practical tool for treatment evaluation.

The investigator have elaborated a specific questionnaire for our CKD patient about cramps. This questionnaire concerns only cramps, regardless of the origin. The first question of the questionnaire will allow to evaluate the prevalence of cramps in our population of CKD patients. Every patient will indicate his medical treatment and biological datas. Only patients who will answer " Yes " to the first question will complete the cramp score of gravity questionnaire. This score is composed of 4 items : frequency of crisis, there impact on sleep, there duration and there intesity Patients will also indicate for how long time there have experimented cramps, the muscular zones involved, associated symptoms, triggering factors, and does something can help them for cramps (medicinal or non medicinal).

The third part concerns there treatment and biological datas. Finally there will complete the QOL-SF12 questionnaire.

Eligibility Criteria:
Inclusion Criteria:

* Voluntary patients with CKD III to V (GFR\<60ml/mn/1,72M2), including dialysed patients (hemodialysis or peritoneal dialysis).
* Non opposed to participate to the research.

Exclusion Criteria:

* Transplanted patient with functional graft.
Assessment of Unilateral Lymphoedema of the Leg

To demonstrate that ImpediMed L-Dex U400 can be used to assess unilateral Lymphoedema of the leg using the same principles for arms.

When Lymphoedema is present, lymph and other fluids build up in the interstitial spaces of the tissues. This results in an overall increase in the total amount of extracellular fluid (ECF) in the limb, causing swelling. This can be documented by measuring the impedance (opposition) to a low frequency current that has been passed into the limb. Low frequency current travels predominantly through the ECF, where the Lymphoedema manifests. As the fluid builds up in the limb, the impedance to the current decreases and it is in this way that low frequency bioimpedance is able to assess Lymphoedema.

Multi-frequency bio-impedance analysis otherwise known as Bioimpedance Spectroscopy (BIS) has been reported to be effective for the measurement of ECF and sub clinical changes in ECF to predict the onset of Lymphoedema in the arms in studies conducted by Cornish et al. It has been reported by Warren et al that BIS can be used as a reliable and accurate tool for documenting presence of lymphoedema in patients with wither upper- or lower-extremity swelling.

The L-Dex U400 device uses an "impedance ratio" methodology to assess unilateral Lymphoedema of the arm. By this method the unaffected arm acts as an internal and subject specific control. The strategy of this study is to show that the L-Dex U400 can use this methodology to assess unilateral leg Lymphoedema.

Eligibility Criteria:
Inclusion Criteria:

Group 1:

* Be between the ages of 18-75 years.
* Self-describe general health as satisfactory.
* Understand the proposed study and be willing and fully able to comply with the study procedures.
* Be a willing participant and be capable of giving and has given informed written consent for entry into the study.
* Have been previously diagnosed, by current clinical practice, as having unilateral Lymphoedema of the leg.

Group 2:

* Be between the ages of 18-75 years.
* Self-describe general health as satisfactory.
* Understand the proposed study and be willing and fully able to comply with the study procedures.
* Be a willing participant and be capable of giving and has given informed written consent for entry into the study.

Exclusion Criteria:

* Have a known heart condition or an implantable device such as a pacemaker or ICD.
* Have a metallic surgical implant (e.g. total hip replacement) not including small implants such as sternal wires or surgical staples.
* Suffer from a renal disorder.
* Be taking diuretic medications.
* Have consumed large amounts of alcohol or caffeinated beverages within six hours of the study.
* Have undertaken excessive exercise within two hours of BIA
* Have a reported fever of \> 38°C at time of screening.
* Be currently in the fourth week of the menstrual cycle.
* Be pregnant or currently breastfeeding.
Pilot Study of TENS for Ocular Pain

Approximately 20% of Veterans have a diagnosis of dry eye (DE) syndrome which is often accompanied by ocular pain that significantly impacts activities of daily living. Currently very few treatments are available for chronic ocular pain, likely because the mechanisms underlying this type of pain have only recently begun to be studied. New treatments that target the neuropathic mechanisms contributing to this type of pain are needed. The proposed research provides a crucial step in addressing the lack of treatments for neuropathic ocular pain by validating the methodology needed to support a randomized controlled trial of transcutaneous electrical nerve stimulation (TENS). TENS is a non-pharmacologic, non-addictive, non-invasive treatment that has been shown to be effective in other chronic pain conditions. The present pilot study aims to address the need for preliminary support of safety and efficacy of TENS for ocular pain, t to advance the study of new treatments for the long-term relief of chronic ocular pain and its impact on health.


Eligibility Criteria:
Inclusion Criteria:

* male or female
* all races and ethnicities
* at least 18 years of age
* persistent eye pain for at least 6 months
* average eye pain intensity of 4 or more on a 0-10 numerical rating scale
* on a stable medication regimen for at least the past 3 months
* naïve to TENS use for orofacial conditions
* eye pain having neuropathic-like characteristics

Exclusion Criteria:

* presence of ocular diseases that are the likely cause of pain (i.e., corneal and conjunctival scarring, corneal edema, uveitis, iris transillumination defects, etc.)
* contraindication to TENS (i.e., pacemaker, cardioverter defibrillator, neuro-stimulation (brain or spinal cord), bone growth stimulations, indwelling blood pressure monitors, epilepsy, pregnancy)
* patients with confirmed signs of tear dysfunction
* current participation in another study with an investigational drug or device within one month prior to screening
A Study of the Safety and Efficacy of Infliximab (Remicade) in Pediatric Patients With Crohn's Disease

A study of the safety and efficacy of infliximab (Remicade) in pediatric patients with moderate to severe Crohn's Disease

This is a medical research study to evaluate the safety and effectiveness of an antibody called infliximab (Remicade) in the treatment of children with Crohn's disease. In this study, subjects will receive multiple doses of infliximab over 62 weeks. The goal of the study is to ensure that the medication is safe and effective in children when it is given for an extended period of time. All subjects will receive an induction regimen of 5 mg/kg infliximab at Weeks 0, 2, and 6. Subjects will then receive either 5 or 10 mg/kg infliximab either every 8 or 12 weeks for up to 46 weeks followed by an open label extension for up to three additional years.

Eligibility Criteria:
Inclusion Criteria:

* Between the ages of 6 and 17 years
* Have had Crohn's disease diagnosed for at least 3 months prior to screening, with gastritis, duodenitis, colitis, ileitis, or ileocolitis, previously confirmed by endoscopy and biopsy
* Have active Crohn's disease despite adequate current treatment with an immunomodulator (ie, AZA, 6-MP, or MTX).

Exclusion Criteria:

* Disease complications for which surgery might be indicated
* Surgery for bowel diversion with placement of a stoma within 3 months prior to screening
* Positive stool examination for enteric pathogens including Giardia lamblia, Clostridium difficile, Shigella species, and Salmonella species.
Movement Enhancing Device for Children

The purpose of this study is to assess: 1) how infants move their bodies to explore, play, and solve problems, 2) if this is different in a high-risk group of infants, and 3) if these abilities can be advanced in a high-risk group through the use of a movement assisting device.

Certain conditions or diagnoses identified soon after birth are known to put infants at risk for having problems with their motor (movement) development as they get older. Infants with these diagnoses are at risk for additional developmental problems due to their inability to move their bodies to explore, learn, and play. This study tests how a device that assists movement can help exploration, learning, and play in children. The information gathered in this study will help us better understand how early learning happens and how we can help individuals become better movers, learners, and problem-solvers so they can increase their participation in everyday play activities.

Eligibility Criteria:
Inclusion Criteria:

• Infants will be invited to participate if they are between 1 month and 6 years and:

* Were born \< 36 weeks of gestational age with periventricular leukomalacia or grade III or IV intraventricular hemorrhage
* Were born \> 36 weeks of gestational age with encephalopathy related to perinatal asphyxia
* Have the diagnosis of neonatal stroke or intracranial hemorrhage
* Have brachial plexus palsy
* Have arthrogryposis multiplex congenital
* Have Down syndrome
* Have congenital hypotonia

Exclusion Criteria:

• blindness or severe sensory motor impairments that would prohibit the child from completing the study assessment.
Fostering Resilience in Physician Moms

Physicians in general are at risk for burnout, and this risk is heightened among women, particularly mothers. In a randomized design, central hypotheses in this study are that mothers who attend our 12-week Relational Psychotherapy Mothers Group (RPMG) intervention will show significantly greater decreases in stress, depression, burnout, and associated risk biomarker indices, as compared to comparison controls (who would meet in unstructured gatherings, for an hour a week for 12 weeks). Additionally the investigators hypothesize that the gains would be maintained three months after the intervention is completed.


Eligibility Criteria:
Inclusion of Women and Minorities:

* This study will be restricted to women physician mothers, who are the target of the manualized RPMG program.
* The study will not use race or ethnicity as a basis for selecting subjects.

Inclusion of Children:

* This study does not include children.

Exclusion criteria

* Participation in this study is open to all Mayo physician mothers with a child under the age of 18 years.
* As in past RPMG trials, the only exclusion criteria are if mothers were to indicate active suicidality, or meet criteria for psychoses, during initial assessments or during participation in this study.
Non-Invasive, Real-Time Technology for Diagnosis of Cervical Tissue

In general, to determine the sensitivity of light transport to tissue from morphological features of clinical significance.

Determine how specific structural features contribute to light scattering. Investigate light scattering differences in tumorigenic and nontumorigenic cells.

Develop and implement quantitative and sensitive methods for measuring morphological properties.

Clinical measurements.

Patients undergoing a colposcopy will also have spectroscopy measurements taken and an extra biopsy of suspicious tissue.

Eligibility Criteria:
Inclusion Criteria:

* Patients with abnormal Pap smears who are referred for colposcopy.

Exclusion criteria include:

* Anyone of the male sex since this study focuses on cervical cell abnormalities
* Any woman who has had a hysterectomy, LEEP, or chemotherapy.
Prevalence of Abnormal Pap Smear

This study aims to evaluate prevalence of abnormal Pap smear among sexually active women of reproductive age attending sohag university hospital outpatient clinic.

This study aims to evaluate prevalence of abnormal Pap smear among sexually active women of reproductive age attending Sohag university hospital outpatient clinic. Participating women will be subjected to accurate history taking regarding age, parity, Body mass index, contraceptive use, menstrual history, and duration of marital life, frequency of previous marriages if any, and the status of cervix by per-vaginal examination of the patients.

The patient put in dorsal lithotomy position and place the feet in stirrups or on foot rests . then, the physician will insert a cusco speculum into the vagina to hold vaginal wall open . The specimens will be collected as follows; firstly, the speculum will be inserted without lubricant. Any mucous, discharge or blood will be removed with dry cotton. A wooden spatula will be used for sampling ectocervix which will be rotated 360 degrees. For sampling endocervix, A brush or a swab will be rotated only 90 degrees as the circumferential bristles will be in contact with the entire surface the moment the brush is inserted.

The samples will be applied to the slides which will be encoded and immediately fixed in 95% ethanol and the samples will be transferred to pathology department to be stained by the standard Papanicolaou stain . The Bethesda System will be used for cytological interpretation.

Eligibility Criteria:
Inclusion Criteria:

* Non pregnant sexually active women aged from 21 to 60 years old.
* Patients who didn't have their pap smear done in last 3 years .
* Patient who had previous abnormal pap smear and coming for follow up.

Exclusion Criteria:

* Women who were diagnosed cervical cancer that was treated.
* Women who underwent total hysterectomy.
* Women who are pregnant.
* Patients whose pap smear was done in last 3 years with reassuring results.
Interaction Between Vanoxerine (GBR 12909) and Cocaine in Cocaine Dependent Individuals

Cocaine dependence is a major public health problem; an effective primary treatment for cocaine dependent individuals has yet to be found. The purpose of this study is to determine the safety and effects of vanoxerine (GBR 12909) in treating cocaine dependent individuals.

Cocaine is a strong central nervous system stimulant that is widely abused throughout the United Sates. Due to its widespread use, it is important to develop an effective treatment for cocaine dependence. Dopamine transporters (DAT) play an important role in the addictive nature of cocaine; the use of compounds that target DAT may be effective in treating cocaine dependent individuals. Research shows that GBR 12909 has a strong affinity for DAT. The purpose of this study is to determine the safety and potential interaction of GBR 12909 and cocaine in cocaine dependent individuals.

Eligibility Criteria:
Inclusion Criteria:

* Meets DSM-IV criteria for current cocaine dependence
* Not currently seeking treatment for cocaine dependence
* Currently uses cocaine, as determined by a self-report and a positive urine test for cocaine, within 30 days prior to study entry
* Within 20 % of ideal body weight, and weighs at least 100 lbs
* Good general health
* Normal electrocardiogram
* Willing to use acceptable methods of contraception for the duration of the study

Exclusion Criteria:

* Current or history of a major psychiatric illness, other than drug dependence or disorders secondary to drug abuse
* Meets DSM-IV criteria for dependence on any drugs other than cocaine, marijuana, nicotine, or alcohol
* Physiologically dependent on alcohol and requires medical detoxification
* Use of prescription drugs within 14 days prior to study entry
* Use of non-prescription drugs within 7 days prior to study entry
* If female, used an oral contraceptive, Depo-Provera, Norplant, or intrauterine progesterone contraceptive system, within 30 days prior to study entry
* Pregnant or breastfeeding
* History of liver disease
* Current elevated aspartate aminotransferase or alanine aminotransferase levels
* Donated a unit of blood within 4 weeks prior to study entry
* Participated in any other clinical investigation within 4 weeks prior to study entry
* History of any illness or behavior that, in the opinion of the investigator, might interfere with the study
* Family history of early significant cardiovascular disease
* Exhibits Hepatitis B surface antigen or Hepatitis C antibody
* HIV infected
* Syphilis
* Active tuberculosis
* Adult asthma
* Chronic obstructive pulmonary disease
* Unable to distinguish between 20 mg and 40 mg of intravenous cocaine
Feasibility Study of a Protocol to Treat Pediatric Oral Mucositis by Low-level Laser Therapy

Low Level Laser Therapy has been used for a few years in some pediatric hospital centers for chemo- and radiotherapy-induced oral mucositis care. It may promote ulceration's healing, limits mucositis severity and associated pain. As its use is recommended in the treatment of radio induced mucositis in adults, the level of evidence in pediatric studies does not allow a precise treatment protocol. The investigators present here the protocol of a feasibility study in the haemato-oncology department of the Children University Hospital of Toulouse, with the view to a future efficacy study.

This study aims to evaluate the feasibility of using low level laser therapy (LLLT) in the haemato-oncology department of the Children University Hospital of Toulouse. The feasibility will be considered as acceptable if 60% of patients hospitalized for oral mucositis had successfully benefit from the procedure. The secondary objectives are the evaluation of efficacy of LLLT on pain and mucositis grade, the evaluation of tolerance of this treatment and the medical time needed for this supportive care. The athermic phototherapy laser diode will be used by scanning the entire oral mucosa area. It will be applied uniformly every two days as long as grade of mucositis is 2 or more, with a fluence of 4J/cm², under two wavelengths (635 nm and 815 nm).

Eligibility Criteria:
Inclusion Criteria:

* Hospitalization in the oncology ward of the university hospital Toulouse France
* Onco-haematological paediatric patients treated by radio- and /or chemo-therapy, affected by an oral mucositis of WHO grade 2 to 4,
* lack of any physical or psychological disease which could interfere with the realization of the study.

Exclusion Criteria:

* Onco-haematological paediatric patients treated by radio- and /or chemo-therapy, affected by an oral mucositis of WHO's grade under 2
* Child suffering from epilepsy
* Patient wearing a cardiac pacemaker
* Patient not able to open their mouth at least 20 mm
* Patient refusing the wearing of safety goggles.